Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.

已完结 10 由 Michael 发布于 2026/7/24 9:38:40

DOI:10.1016/S2213-2600(23)00158-3
作者：Bruno Fran?ois, Simon Lambden, Tom Fivez, Sebastien Gibot, Marc Derive, Jean-Marie Grouin, Margarita Salcedo-Magguilli, Jérémie Lemarié, Nicolas De Schryver,
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Background: Activation of the triggering receptor expressed on myeloid cells-1 (TREM-1) pathway is associated with septic shock outcomes. Data suggest that modulation of this pathway in pati

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SageNINJ1 Aggravates Doxorubicin-Induced Cardiotoxicity by Suppressing AMPK-Mediated HIF-1α Deubiquitination.